(Bloomberg) -- US scientists haven’t gotten a handle on how to effectively track bird flu, three months after a Texas dairy worker was diagnosed with the virus. That’s impeding the ability to create a vaccine to protect against the spread among people.Most Read from BloombergDemocrats Weigh Mid-July Vote to Formally Tap Biden as NomineePowerful Storm Beryl Aims at Jamaica After Grenada StrikeS&P 500 Closes Above 5,500 in Record-Breaking Run: Markets Wrap‘Upflation’ Is the New Retail Trend Drivin
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To Buy […]
Shares of GSK (GSK) are falling after a Centers for Disease Control and Prevention (CDC) committee shifted its recommendation on Respiratory Syncytial Virus (RSV) vaccination dosages. Yahoo Finance reporter Anjalee Khemlani joins Morning Brief to break down this latest development for GSK and what the CDC announcement could mean for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino.